NCT05294627已完成不适用
Validation of the Prostate Cancer Biomarker Stockholm3 for Improved Disease Detection and Classification in the Swiss Population
University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 380 人开始时间: 2020年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 380
- 试验地点
- 1
- 主要终点
- Cancer detection
研究概览
简要总结
The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based on a combination of elevated PSA levels (e.g. >2.5 ng/ml) and/or pathological digital rectal examination and/or MRI-findings.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Planned prostate biopsy due to suspicion of prostate cancer (usually due to a combination of elevated PSA levels [e.g. >2.5 ng/ml] and/or pathological digital rectal examination and/or MRI-findings)
- •Written informed consent by the participant
排除标准
- •Severe anemia (Hb <60g/l)
- •Previously already established diagnosis of prostate cancer.
结局指标
主要结局
Cancer detection
时间窗: 2020-2022
Correlation between Stockholm3 and histological diagnosis of prostate cancer
次要结局
- Disease state(2020-2022)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate BiopsyProstate CancerNCT00966095Source MDx1,200
撤回
不适用
Investigation of Urinary Biomarkers for the Detection of Prostate CancerUrineLiquid BiopsyProstate CancerNCT05454371Novosanis NV
已完成
不适用
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate BiopsyProstate CancerNCT00373035Wake Forest University Health Sciences60
撤回
不适用
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation ToxicityProstate CancerNCT04580667DiaCarta, Inc.250
进行中（未招募）
2 期
Prostate Cancer Biomarker Enrichment and Treatment SelectionProstate CancerNCT03385655Canadian Cancer Trials Group200